Dawn Mattoon, PhD

Chief Executive Officer

Dr. Dawn Mattoon is the Chief Executive Officer at Mercy Bioanalytics. She brings nearly 20 years of experience in the biotechnology industry and has held leadership positions in R&D, Strategy, and General Management for leading companies including Invitrogen, Life Technologies, Thermo Fisher, and Cell Signaling Technology. Most recently Dr. Mattoon served as the Senior Vice President for Clinical Diagnostics at Quanterix, where she led the development and commercialization of the company’s first two FDA authorized diagnostic tests for COVID-19, and received Breakthrough Device designations from the FDA for diagnostic tests in Alzheimer’s Disease and Multiple Sclerosis. She has developed and commercialized products across a range of proteomic and genomic technologies, and is thrilled by the opportunity to bring the highly innovative Mercy Halo diagnostic test portfolio to patients.

Dr. Mattoon earned her Ph.D. in Genetics with a focus in signal transduction from Yale University, where she also completed her postdoctoral fellowship.

Toumy Guettouche, PhD

Chief Scientific Officer

Dr. Toumy Guettouche is the Chief Scientific Officer at Mercy BioAnalytics.  He brings nearly 20 years of experience in the genomics, proteomics, and molecular diagnostics space. Before joining Mercy BioAnalytics, he held various leadership positions in R&D in the areas of women’s health, oncology, genetics and single cell technology at Roche Sequencing, Grail, and Scale Biosciences. Under his leadership, Toumy’s teams have successfully launched numerous products both in the areas of automation, target enrichment, and single cell analysis, and he has contributed to multiple LDT launches and US FDA IVD applications.

Dr. Guettouche earned a Bachelor of Science in Biology from the University of Potsdam, Germany, and a PhD in Molecular Biology and Biochemistry from the University of Miami’s School of Medicine. He held a faculty position in the Department of Genetics at the University of Miami. Toumy has co-authored numerous studies in high-impact journals and holds patents in the fields of genomics and proteomics.

Darrin Crisitello

Darrin Crisitello is Chief Commercial Officer at Mercy BioAnalytics. He brings over 20 years of commercial leadership and execution across diagnostics, life sciences, and healthcare technology companies.

Over the course of his career, he has built and scaled multiple early-stage global commercial organizations and led the launch of diagnostic products spanning women’s health, oncology, and neurology. Prior to joining Mercy BioAnalytics, Darrin served as Chief Commercial Officer at Quanterix, where he led commercialization of ultra-sensitive biomarker platforms foundational to early disease detection. He has also held senior leadership roles at Natera, leading the launch of the Panorama non-invasive prenatal test and supporting the company’s 2015 IPO, as well as at Color Health, where he was responsible for early commercial growth.

Darrin holds a BS in Biology and Chemistry from Moravian College and an MBA from the University of Massachusetts and is deeply committed to advancing earlier, more accurate cancer detection to improve patient outcomes.

Josh Gralapp

Vice President, Commercial

Josh Gralapp is the Vice President, Commercial at Mercy BioAnalytics. He is a 20+ year veteran of the biotechnology industry, bringing broad experience across research, portfolio strategy and evaluation, management consulting, and marketing and product strategy leadership to Mercy. Most recently, he was the VP of Commercial at Delfi Diagnostics, where he led the product definition, commercialization strategy, commercial team build out, and launch plan development. He was also the key commercial lead through Series A and B financing, leading to over $230M in funding.

Prior to his time at Delfi, Josh led the urology product portfolio at Genomic Health and successfully launched their first liquid biopsy assay, Oncotype AR-V7 Nucleus Detect. Josh was a senior consultant at Applied Strategies where he conducted critical portfolio analyses for nonprofits such as the Gates foundation and the International Vaccine Institute and is an inventor on several pharmaceutical patents from his time as a medicinal chemist.

Ronan O’Brien

Chief Legal Officer

Ronan is the Chief Legal Officer at Mercy BioAnalytics. He is a seasoned life sciences executive for public and private companies who, over a 30-year career, has helped guide organizations through transformational periods of change.

Prior to Mercy, Ronan was the Chief Legal Officer at Lyra Therapeutics (Nasdaq: LYRA), which developed a drug-device combination product for the treatment of chronic rhinosinusitis. Before then, Ronan was the General Counsel at Pear Therapeutics (Nasdaq: PEAR), which launched three products commercially for the treatment of opioid use disorder, substance use disorder and insomnia. Ronan’s executive experience includes working closely with Boards and management teams to establish effective legal functions, build compliance programs, complete equity and debt financings, enable IPO readiness, oversee public company reporting and close strategic transactions.

Prior to becoming a life sciences executive, Ronan was a corporate lawyer at several national law firms and was a partner at two of them. Ronan received a BA in English and French Literature and a JD from Boston University.

Tatia Troy

Vice President, Human Relationship

Tatia Troy is Vice President of Human Relationships at Mercy BioAnalytics. She brings more than 25 years of executive leadership experience across healthcare, biotechnology, and life sciences organizations, with significant expertise building and scaling people functions for early-stage and high-growth companies.

Throughout her career, Ms. Troy has partnered with executive leadership teams to align talent strategy, organizational design, and culture with business objectives and operational growth. Prior to joining Mercy BioAnalytics, she held executive leadership roles at Johnson & Johnson and multiple emerging biotech organizations, where she led organizational transformation, talent strategy, compensation and succession planning, and the development of scalable HR infrastructure to support growth and business performance. 

Ms. Troy earned a B.A. in Communications from George Mason University. 

Michael Smith

Senior Vice President, Operations

Michael Smith is the Senior Vice President, Operations at Mercy BioAnalytics. He brings over 15 years of experience in the in vitro diagnostic industry with experience in product development, manufacturing, quality assurance, regulatory affairs, and clinical affairs. Most recently, Michael served as the Director or Regulatory and Clinical Affairs at MDC Associates, where he led a team of regulatory specialists and clinical researchers to support dozens of companies in their efforts to bring new products to the market. He has worked with the FDA on 15 premarket applications, both 510(k) and PMA throughout his career covering a multitude of diagnostic technologies.

Ellen Snow

Chief Financial Officer

Ellen is the Chief Financial Officer at Mercy BioAnalytics. She brings more than two decades of financial leadership with deep experience driving transformation and value creation across public and private companies. Over the course of her career, she has guided organizations through IPO readiness, restructurings, and growth initiatives, consistently translating financial complexity into clear, actionable insights for boards, investors, and cross-functional teams.

Prior to joining Mercy BioAnalytics, Ellen held senior finance leadership roles across the life science sector, including medical device, pharmaceutical, and MedTech, where she built high-performing teams and strengthened governance during periods of rapid change. At Mercy, she applies operational rigor, integrity, and a relentless focus on scalable growth to advance the company’s mission of transforming early cancer detection.

Ellen is a graduate of Merrimack College and began her career in public accounting working for two of the Big Four firms, in both audit and transaction services. Ellen is a Certified Public Accountant.

Tim Membrino

Vice President of Program & Portfolio Management

Tim Membrino is the Vice President of Program & Portfolio Management at Mercy BioAnalytics. He has over 30 years of experience in product development and project management across various industries including in vitro diagnostics, medical devices and genomics and proteomics products. Most recently Tim served as V.P. Program & Portfolio Management at Quanterix where he led growth of the Program Management Office to deliver program and project leadership across the breadth of the business portfolio. He has extensive experience executing product development initiatives within regulated environments with deep knowledge of FDA 21 CFR Part 820 Quality Systems including product development consistent with Design Controls.

Tim earned a BS degree in Mechanical Engineering from Worcester Polytechnic Institute, a MS degree in Aerospace Engineering from Embry-Riddle Aeronautical University and is PMP and Agile Scrum Master certified.

Dr. Prasanth Reddy

Chief Medical Officer

Dr. Reddy is a distinguished physician and executive with more than 25 years of experience across clinical practice and biotech leadership and is triple board-certified in internal medicine, medical oncology, and hematology. He most recently served as the Global Head of Enterprise Oncology at LabCorp, where he led the integration of genomic profiling capabilities including the acquisitions of OmniSeq and PGDx. Prior to this role, he was the VP of Medical Affairs at Foundation Medicine, where he led the development and execution of medical strategy worldwide, advancing the clinical adoption of precision oncology through data-driven evidence generation, KOL engagement, and strategic collaborations.

Dr. Reddy earned his medical degree from the University of Kansas Medical Center, where he also completed his residency in internal medicine and fellowship in hematology and oncology. He holds a Master of Public Health from the University of Kansas and is an alumnus of Harvard Business School. Dr. Reddy also serves as a Lieutenant Colonel in the U.S. Air Force Reserve, with nearly two decades of service to his country.

Stanley Lapidus

Chairman

• 30+ years successfully inventing and commercializing early cancer detection diagnostics
• Founded Cytyc, which revolutionized the Pap smear. Acquired for $6 billion
• Founded Exact Sciences which revolutionized early detection of colorectal cancer. Exact’s market capitalization has exceeded $22 billion

Paul Blavin

Co-Founder & Vice Chairman

• Serial entrepreneur and successful value investor

• Over 16 years, built and led a successful $2bn+ private investment partnership

• Founder of several highly successful social ventures

• Sole Funder of Mercy ($5.5 million) inception to November 2020

Paul Meister

• Retired Chairman of the Board of Thermo Fisher Scientific, Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo

• President of MacAndrews & Forbes Incorporated from 2014-2018

• Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting, and clinical research services to the pharmaceutical and biotech industries from 2010-2014

• Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.)

Dr. Myla Lai-Goldman

Dr. Myla Lai-Goldman is a co-founder and Chairperson of GeneCentric Therapeutics, a precision medicine company in Durham, NC, where she previously served as CEO and President.  She is also a venture partner with Hatteras Venture Partners and managing partner of Personalized Science, LLC, a diagnostic consulting company that she founded in 2008.  In addition to GeneCentric, Dr. Lai-Goldman serves on the boards of West Pharmaceutical Services, Akoya Biosciences, Qvella Corporation, and NovoPath. 

Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical and Chief Scientific Officer.  She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people.  During her tenure at LabCorp, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays.  Her experience includes the development of partnerships, licensing and acquisitions. She is a recognized speaker and author on understanding and overcoming the barriers to test adoption. 

Dr. Lai-Goldman received her BS from the University of Pennsylvania and MD from Columbia University College of Physicians and Surgeons.  She is board-certified in anatomic and clinical pathology.  She brings her unique perspective as a physician, researcher, corporate executive and board-member to her work. 

Rob Freelen

Rob Freelen is currently Managing Director and investing partner at Sozo Ventures. He is also a co-founder of LA-based FinTech company, Turbine Finance, a former SVB executive, and a Kauffman Fellow. Immediately prior to joining Sozo, Rob co-founded Turbine Finance. Rob previously served as Silicon Valley Bank’s Head of Venture Capital Relationship Management where he was the bank’s principal advisor to SVB Capital’s Fund-of-Funds and primary relationship manager for many of the top US Venture Capital firms. Rob has a B.A. in Psychology from Whitman College and has lectured at UCLA, USC, and Stanford on venture capital and venture lending.

Sonja Hoel Perkins

• Managing Director of The Perkins Fund, has been investing in high technology for over 30 years

• Youngest General Partner in Menlo Ventures’ history. Awarded the Menlo Ventures “Investor of the Year Award” six times in seventeen years

• Invested in several startups that have achieved multi-billion-dollar valuations including Acme Packet, F5 Networks and McAfee Associates

• Worth Magazine has ranked her among the 100 Most Powerful People in Finance in the World

• Invested in over 60 companies throughout her VC career

David Ransohoff, M.D.

• Professor of Medicine and Epidemiology, University of North Carolina at Chapel Hill

• Pioneer in clinical trials to evaluate molecular biomarker discovery

• First “Rules of evidence” to evaluate diagnostic tests (NEJM 1978), cited 1500 times; methods papers in Science, Nature Reviews

• Guidelines-making: advisor to US Preventive Services Task Force

• Co-PI on Exact Science clinical study

Steven Skates, Ph.D.

• Associate Professor of Medicine (Biostatistics), Harvard Medical School
• Over 25 years and co-author of 50+ peer-reviewed articles on the early detection of ovarian cancer
• Trial Management Committee of UKCTOCS, the world’s largest prospective ovarian cancer screening trial (215,000+ women over 15 years)
• Co-inventor of ROCA, Risk of Ovarian Cancer Algorithm

Christine Berg, M.D.

• Senior author on five early cancer detection randomized control trials. Project officer for the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), a randomized control trial with 155,000 participants and the National Lung Screening Trial with 53,454 participants
• 40 years as a practicing physician. Research focus on cancer screening
• Chief, Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (2004-2012)
• Author, over 130 Peer Reviewed Original Scientific Publications, 10 Publications, New England Journal of Medicine